Ncardia is a human iPSC technology company that operates worldwide with facilities, offices and staff throughout Europe and North America. We work with biopharmaceutical companies in drug discovery and cell therapy worldwide, to leverage the power of stem cell technologies in the development of novel therapies of multiple modalities at any stage of development.
Over the past 10 years, we have built the expertise and infrastructure required to differentiate, manufacture and characterize high-quality iPSC-derived cell and disease models. We can facilitate the process of disease modeling and high-throughput screening to accelerate drug discovery. In addition, our deep knowledge of and experience in cell biology and large-scale manufacturing capabilities enable the development of robust iPSC-based allogenic cell therapies in multiple therapeutic areas.
We listen to our customer’s project plans, questions and challenges, and co-develop human iPSC-based solutions that fit their specifications.
Explore our website to learn more www.ncardia.com.
Location: Belgium, Hainaut, Gosselies
Member count: 51-200
Total raised: $72.380542M
Founded date: 2011
Investors 2
| Date | Name | Website |
| - | Le Groupe ... | sriw.be |
| - | SFPIM | sfpim.be |
Funding Rounds 2
| Date | Series | Amount | Investors | Deal News |
| 16.11.2021 | - | $60M | - | - |
| 17.11.2017 | Series B | $12.380542... | - | finsmes.co... |
Mentions in press and media 4
| Date | Title | Description | Category | Author | Source |
| 21.11.2022 | Prepaire™ ... | Ncardia to develop and manufac... | - | - | einpresswi... |
| 16.11.2021 | Casper tur... | This is the web version of Ter... | - | - | fortune.co... |
| 16.11.2021 | Ncardia Se... | Ncardia, a leader in developin... | - | - | marketscre... |
| 17.11.2017 | Ncardia Co... | Ncardia, a Gosselies, Belgium-... | Belgium | - | finsmes.co... |